Corcept Therapeutics (NASDAQ:CORT) Releases Quarterly Earnings Results, Misses Estimates By $0.11 EPS

Corcept Therapeutics (NASDAQ:CORT) posted its quarterly earnings results on Wednesday. The biotechnology company reported $0.26 EPS for the quarter, missing the consensus estimate of $0.37 by ($0.11), Zacks reports. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The company had revenue of $181.89 million for the quarter, compared to analysts’ expectations of $200.12 million. Corcept Therapeutics updated its FY 2025 guidance to EPS.

Corcept Therapeutics Price Performance

Shares of NASDAQ CORT opened at $59.85 on Friday. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01. Corcept Therapeutics has a twelve month low of $20.84 and a twelve month high of $75.00. The stock has a 50 day moving average of $59.60 and a two-hundred day moving average of $51.16. The stock has a market cap of $6.27 billion, a P/E ratio of 47.50 and a beta of 0.58.

Insider Transactions at Corcept Therapeutics

In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the company’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $59.46, for a total value of $130,812.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Sean Maduck sold 20,000 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $50.39, for a total value of $1,007,800.00. Following the sale, the insider now directly owns 85,318 shares in the company, valued at approximately $4,299,174.02. The trade was a 18.99 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,600 shares of company stock worth $1,399,576 over the last 90 days. 20.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. StockNews.com lowered Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, November 25th. Canaccord Genuity Group boosted their price objective on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a report on Thursday, January 30th. HC Wainwright restated a “buy” rating and issued a $115.00 price objective on shares of Corcept Therapeutics in a report on Thursday. Finally, Piper Sandler boosted their price objective on shares of Corcept Therapeutics from $67.00 to $78.00 and gave the company an “overweight” rating in a report on Thursday. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $99.75.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.